来源：乐凯胶片公告 1月13日，乐凯胶片通过公告披露，其控股子公司乐凯光电计划使用自有资金投资建设一条TAC功能膜涂布生产线。该项目位于江苏省宿迁市宿城经济开 发区西片区，总投资额约为9766.75万元。该项目的建设周期预计为24个月。 根据公告内容，该生产线将主要用于生产TAC功能膜中的防眩光硬化膜。其设计产能为最大幅宽1540毫米，生产车速为每分钟30米。项目完全达产后，预 计将实现年产1800万平方米TAC功能膜的生产能力。乐凯胶片表示，项目满产后预计可实现年销售收入约2亿元。 乐凯光电拟在江苏省宿迁市宿城经济开发区西片区投资建设 TAC 功能膜涂布生产线项目，项目总投资预计 9,766.75 万元，项目拟建设精密涂布线 1 条。 新增主要工艺设备 17 台（套），其中进口设备 3 台（套），国产设备 14 台（套）。项目主要产品为 TAC 功能膜（防眩光硬化膜(AG)）。 乐凯胶片在公告中指出，TAC功能膜是TAC膜经过进一步功能化处理的下游产品，广泛应用于平板显示产业链。此次投资旨在延伸乐凯光电在TAC膜领域 的产业链布局，并提升其在偏光片及光学膜领域的综合竞争力。公告提及，随着全球液晶面板制造重心 ...

1月13日，乐凯胶片公告， 公司控股子公司乐凯光电计划使用自有资金投资建设TAC功能膜涂布 生产线项目，投资金额估算为 9,766.75万元 。 根据公告，该项目选址江苏省宿迁市宿城经济开发区西片区，规划建设精密涂布生产线1条，配套 新增工艺设备17台（套），包括进口设备3台（套）和国产设备14台（套）。项目主要产品为 TAC功能膜（防眩光硬化膜(AG)），设计产品最大幅宽1,540mm，生产车速30m/min，达产后 具备年产TAC功能膜1,800万平方米的生产能力。 据了解，TAC膜是LCD偏光片的关键组成部分。偏光片是LCD显示的核心元件之一，而TAC膜作 为偏光片的保护层，具有高透光率、低雾度和良好的耐候性，能保护内部的偏振膜（如PVA膜） 免受水分、紫外线和机械损伤，同时确保光线均匀透过，提升显示画面的清晰度和稳定性。 乐凯胶片表示， TAC功能膜属于TAC膜的下游产业，是TAC膜的进一步功能化处理，通过本项目 建设将延伸乐凯光电TAC膜产业链，促进TAC膜的品质完善和提高，进一步提升公司在偏光片光 学膜领域的总体实力与竞争能力。 资料显示，乐凯胶片主营方向为图像信息材料和新能源材料，旗下多家控股公 ...

Group 1 - Shoukai Co. achieved a signed area of 125.72 million square meters and a signed amount of 17.845 billion yuan in 2025 [1] - Tongda Hai expects a net loss for the year 2025 [2] - Jiuri New Materials' subsidiary has entered the trial production phase for a project with an annual capacity of 350 tons of hydroxy ketone [3] Group 2 - Jixin Technology's shareholder plans to reduce their stake by up to 1% [4] - Fulai New Materials received approval from the CSRC for a stock issuance [5] - Yaqi International plans to sign a strategic cooperation framework agreement with Zhongnong Holdings [6] Group 3 - Sanwei Co.'s controlling shareholder plans to transfer up to 5.10% of shares [7] - Lekai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film production line [8] - China Power Construction's subsidiary signed two major contracts totaling approximately 15.589 billion yuan [9] Group 4 - Shunhao Co. plans to increase its investment in a subsidiary by 74.98 million yuan [10] - Jieneng Wind Power reported a cumulative power generation of 12.417 billion kWh in 2025, a year-on-year increase of 1.43% [11] - Zhongjian Technology's H-share issuance application has been accepted by the CSRC [12] Group 5 - Hendi Pharmaceutical expects a net profit decrease of 57.4% to 66.14% in 2025 [13] - Haopeng Technology anticipates a net profit increase of 113.69% to 141.09% in 2025 [14] - Lingang Co. expects a net loss of 1.45 billion to 1.67 billion yuan in 2025 [15] Group 6 - Chuan Investment Energy reported a cumulative power generation of 6.627 billion kWh in 2025, a year-on-year increase of 13.85% [16] - Tengyuan Cobalt expects a net profit increase of 50.02% to 69.87% in 2025 [17] - Huazhi Jie plans to repurchase shares worth 30 million to 50 million yuan [18] Group 7 - Opto has won a bid for a 120 million yuan project from GoerTek [19] - Shanghai Construction reported a new contract amount of 252.942 billion yuan in 2025, a year-on-year decrease of 34.98% [20] - Hangfa Control expects a net profit decrease of 52.02% to 58.02% in 2025 [22] Group 8 - Shimao Energy is planning a change in control and will continue to suspend trading [23] - Shenwan Hongyuan Securities received approval for a bond issuance of up to 60 billion yuan [24] - Jingjiawei signed a strategic cooperation letter of intent with Jing'an Technology [25] Group 9 - Pianzaihuang completed the first subject enrollment for a clinical trial of a new drug [26] - Placo's subsidiary received a new veterinary drug registration certificate [27] - Zhongli Co. plans to reduce its stake by up to 0.75% [28] Group 10 - Solar Energy received renewable energy subsidies of 3.318 billion yuan in 2025, a year-on-year increase of 142.9% [29] - Palm Co. has filed a lawsuit to recover 144 million yuan in project payments [30][31] - Yongjin Co. plans to invest 2.658 billion yuan in a new stainless steel project [32] Group 11 - BAIC Blue Valley plans to increase its stake by 14.5 million to 16.4 million yuan [33] - Lingyun Light's stock issuance application has been approved by the CSRC [34] - Hongbo New Materials expects a net loss in 2025 [35] Group 12 - Shanghai Pharmaceuticals received approval for the listing of a new antifungal drug [36] - Changjiang Electric reported a net profit of 34.167 billion yuan in 2025, a year-on-year increase of 5.14% [37] - Weilan Bio received a new veterinary drug registration certificate [38] Group 13 - Pingzhi Information's subsidiary is expected to win a procurement project worth approximately 37.5884 million yuan [39]